From bench to almost bedside: The long road to a licensed ebola virus vaccine

Gary Wong; Emelissa J. Mendoza; Francis A. Plummer; George F. Gao; Gary P. Kobinger; Xiangguo Qiu

doi:10.1080/14712598.2018.1404572

From bench to almost bedside: The long road to a licensed ebola virus vaccine

Gary Wong, Emelissa J. Mendoza, Francis A. Plummer, George F. Gao, Gary P. Kobinger, Xiangguo Qiu

Research output: Contribution to journal › Review article › peer-review

Abstract

Introduction: The Ebola virus (EBOV) disease epidemic during 2014–16 in West Africa has accelerated the clinical development of several vaccine candidates that have demonstrated efficacy in the gold standard nonhuman primate (NHP) model, namely cynomolgus macaques. Areas covered: This review discusses the pre-clinical research and if available, clinical evaluation of the currently available EBOV vaccine candidates, while emphasizing the translatability of pre-clinical data generated in the NHP model to clinical data in humans. Expert opinion: Despite the existence of many successful EBOV vaccine candidates in the pre-clinical stages, only two platforms became the focus of Phase 2/3 efficacy trials in Liberia, Sierra Leone, and Guinea near the peak of the epidemic: the Vesicular stomatitis virus (VSV)-vectored vaccine and the chimpanzee adenovirus type 3 (ChAd3)-vectored vaccine. The results of three distinct clinical trials involving these candidates may soon pave the way for a licensed, safe and efficacious EBOV vaccine to help combat future epidemics.

Original language	English (US)
Pages (from-to)	159-173
Number of pages	15
Journal	Expert Opinion on Biological Therapy
Volume	18
Issue number	2
DOIs	https://doi.org/10.1080/14712598.2018.1404572
State	Published - Nov 17 2018
Externally published	Yes

Keywords

Clinical trials
Ebola virus
Nonhuman primates
Vaccines

ASJC Scopus subject areas

Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.1080/14712598.2018.1404572

Cite this

@article{33657eda3dc84422a1580bbd2af0beba,

title = "From bench to almost bedside: The long road to a licensed ebola virus vaccine",

abstract = "Introduction: The Ebola virus (EBOV) disease epidemic during 2014–16 in West Africa has accelerated the clinical development of several vaccine candidates that have demonstrated efficacy in the gold standard nonhuman primate (NHP) model, namely cynomolgus macaques. Areas covered: This review discusses the pre-clinical research and if available, clinical evaluation of the currently available EBOV vaccine candidates, while emphasizing the translatability of pre-clinical data generated in the NHP model to clinical data in humans. Expert opinion: Despite the existence of many successful EBOV vaccine candidates in the pre-clinical stages, only two platforms became the focus of Phase 2/3 efficacy trials in Liberia, Sierra Leone, and Guinea near the peak of the epidemic: the Vesicular stomatitis virus (VSV)-vectored vaccine and the chimpanzee adenovirus type 3 (ChAd3)-vectored vaccine. The results of three distinct clinical trials involving these candidates may soon pave the way for a licensed, safe and efficacious EBOV vaccine to help combat future epidemics.",

keywords = "Clinical trials, Ebola virus, Nonhuman primates, Vaccines",

author = "Gary Wong and Mendoza, {Emelissa J.} and Plummer, {Francis A.} and Gao, {George F.} and Kobinger, {Gary P.} and Xiangguo Qiu",

note = "Publisher Copyright: {\textcopyright} 2017 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = nov,

day = "17",

doi = "10.1080/14712598.2018.1404572",

language = "English (US)",

volume = "18",

pages = "159--173",

journal = "Expert Opinion on Biological Therapy",

issn = "1471-2598",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - From bench to almost bedside

T2 - The long road to a licensed ebola virus vaccine

AU - Wong, Gary

AU - Mendoza, Emelissa J.

AU - Plummer, Francis A.

AU - Gao, George F.

AU - Kobinger, Gary P.

AU - Qiu, Xiangguo

PY - 2018/11/17

Y1 - 2018/11/17

N2 - Introduction: The Ebola virus (EBOV) disease epidemic during 2014–16 in West Africa has accelerated the clinical development of several vaccine candidates that have demonstrated efficacy in the gold standard nonhuman primate (NHP) model, namely cynomolgus macaques. Areas covered: This review discusses the pre-clinical research and if available, clinical evaluation of the currently available EBOV vaccine candidates, while emphasizing the translatability of pre-clinical data generated in the NHP model to clinical data in humans. Expert opinion: Despite the existence of many successful EBOV vaccine candidates in the pre-clinical stages, only two platforms became the focus of Phase 2/3 efficacy trials in Liberia, Sierra Leone, and Guinea near the peak of the epidemic: the Vesicular stomatitis virus (VSV)-vectored vaccine and the chimpanzee adenovirus type 3 (ChAd3)-vectored vaccine. The results of three distinct clinical trials involving these candidates may soon pave the way for a licensed, safe and efficacious EBOV vaccine to help combat future epidemics.

AB - Introduction: The Ebola virus (EBOV) disease epidemic during 2014–16 in West Africa has accelerated the clinical development of several vaccine candidates that have demonstrated efficacy in the gold standard nonhuman primate (NHP) model, namely cynomolgus macaques. Areas covered: This review discusses the pre-clinical research and if available, clinical evaluation of the currently available EBOV vaccine candidates, while emphasizing the translatability of pre-clinical data generated in the NHP model to clinical data in humans. Expert opinion: Despite the existence of many successful EBOV vaccine candidates in the pre-clinical stages, only two platforms became the focus of Phase 2/3 efficacy trials in Liberia, Sierra Leone, and Guinea near the peak of the epidemic: the Vesicular stomatitis virus (VSV)-vectored vaccine and the chimpanzee adenovirus type 3 (ChAd3)-vectored vaccine. The results of three distinct clinical trials involving these candidates may soon pave the way for a licensed, safe and efficacious EBOV vaccine to help combat future epidemics.

KW - Clinical trials

KW - Ebola virus

KW - Nonhuman primates

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85053526152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053526152&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1404572

DO - 10.1080/14712598.2018.1404572

M3 - Review article

C2 - 29148858

AN - SCOPUS:85053526152

SN - 1471-2598

VL - 18

SP - 159

EP - 173

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

IS - 2

ER -

From bench to almost bedside: The long road to a licensed ebola virus vaccine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this